Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients.

Stephen B WilliamsVidit SharmaDavid H JiangHolly K Van HoutenLindsey R SangaralinghamBijan J BorahEugene D KwonDavid F PensonStacie B DusetzinaJon C TilburtStephen A Boorjian

Published in: The Journal of urology (2022)

Patients receiving novel hormonal therapy for advanced prostate cancer had substantially higher treatment-related out-of-pocket costs. In addition to raising awareness among prescribers, these data support the inclusion of treatment associated financial toxicity in shared decision making for advanced prostate cancer and call attention to subgroups of patients particularly vulnerable to financial toxicity.

Keyphrases

prostate cancer
end stage renal disease
radical prostatectomy
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
oxidative stress
patient reported outcomes
type diabetes
skeletal muscle
working memory
risk factors
health insurance